Multiorgan, Multimodality Imaging in Cardiometabolic Disease

Kumar, Vidhya; Hsueh, Willa A.; Raman, Subha V.

doi:10.1161/circimaging.117.005447

Cited by 8 publications

(7 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2c and Extended Data Figs. [1][2][3]. For instance, in RNA-seq data comparing the atherosclerotic aortic arterial wall (AOR) of individuals with CAD with the healthy aortic wall of controls, coding genes were equally upregulated and downregulated (n = 1,727 and 1,652, respectively), whereas noncoding genes were predominantly upregulated (n = 9,047 and 560).…”

Section: Resultsmentioning

confidence: 99%

“…12 ) (the 'GRN' definition used in the current study). This broader correlation-based definition of GRNs has become widely accepted, because (1) it helps to answer concrete biological questions, and (2) it addresses limitations that are inherent in the traditional definition of gene-regulatory networks. A fundamental question in complex disease genetics is how genetic variation affects disease traits.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A mechanistic framework for cardiometabolic and coronary artery diseases

et al. 2022

View full text Add to dashboard Cite

yocardial infarction and stroke, the leading causes of global morbidity and mortality, are caused by atherosclerosis, which originates from inflammatory, lipid, endocrine, metabolic and hemodynamic disturbances. Indeed, multiple and parallel malfunctions in metabolic organs are responsible for the complex molecular disease processes of cardiometabolic disorders (CMDs) leading to CAD 1 . For example, the liver plays a central role in determining plasma lipid levels by regulating lipoprotein synthesis and lipoprotein remnant uptake, whereas adipose tissues and skeletal muscle (SKLM) facilitate lipolysis. Similarly, blood glucose levels depend on a delicate interplay of hepatic glucose production, insulin production in pancreatic beta cells and insulin sensitivity in peripheral glycolytic tissues. Alterations in lipid or glucose metabolism may lead to obesity, which in turn may promote the development of type 2 diabetes mellitus, hypertension, systemic inflammation 2,3 and, eventually, CAD.Thus far, the role of these and other risk factors in causing the initiation and progression of CAD have typically only been considered in isolated pathways. A systemic view 4-7 of the combined high-dimensional, multiorgan metabolic processes that perturb the biology of the arterial wall has, however, not been described. Systems studies based on integrative analyses of DNA and RNA sequencing (RNA-seq) data, unlike studies focusing on DNA alone, such as genome-wide association studies (GWAS), hold promise to go beyond studies of individual genetic risk loci and candidate genes in isolated pathways by capturing the combined impact of exogenous and genetic risk factors 8-10 . To achieve this, RNA-seq data are typically first used to infer gene coexpression modules 5 ,

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A mechanistic framework for cardiometabolic and coronary artery diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Many studies have reported that NAFLD is more common in patients with IHD and combines many common risk factors, such as DM and obesity [ 2 , 5 , 6 , 11 ]. In this study, we defined MAFLD using the definition proposed by Eslam et al [ 12 ] and showed that 48.9% of patients had MAFLD.…”

Section: Discussionmentioning

confidence: 99%

“…The association between MAFLD and physical dysfunction in patients with IHD can be attributed to several underlying mechanisms. Patients with NAFLD are often reported to develop sarcopenia; this can be attributed to the presence of insulin resistance, excess adipose tissue, and chronic low-grade inflammation in this population [ 1 , 6 , 36 ]. Hepatic steatosis and the resulting NAFLD can lead to additional chronic inflammation by secretion of inflammatory cytokines such as IL6, TNF-alpha, and leptin [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nonalcoholic fatty liver disease (NAFLD) is recognized as the most prevalent chronic liver disease worldwide, with an estimated global prevalence of 20–30% [ 1 , 2 , 3 ]. NAFLD is a multisystem disease that affects organs and regulatory pathways other than the liver [ 4 , 5 , 6 , 7 ]. Liver fibrosis caused by NAFLD progression is associated with increased mortality [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome

Noda

Kamiya

Hamazaki

et al. 2022

JCM

View full text Add to dashboard Cite

It is believed that patients with acute coronary syndrome (ACS) are at an increased risk of nonalcoholic fatty liver disease (NAFLD), which can lead to sarcopenia and physical dysfunction. However, the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and physical dysfunction and prognosis remains unclear. We investigated the prevalence of MAFLD in patients with ACS to assess the relationship between MAFLD and muscle strength, walking speed, and 6-min walking distance (6 MWD). We reviewed patients with ACS who were assessed for hepatic steatosis using the fatty liver index, and the results were further assessed to determine the presence of MAFLD. Among 479 enrolled hospitalized patients, MAFLD was identified in 234 (48.9%) patients. Multiple regression analysis revealed that MAFLD was independently associated with lower leg strength, gait speed, and 6 MWD (leg strength, p = 0.020; gait speed, p = 0.003 and 6 MWD, p = 0.011). Furthermore, in multivariate Poisson regression models after adjustment for clinical confounding factors, combined MAFLD and reduced physical functions were significantly associated with a higher incidence of clinical events. MAFLD is common in hospitalized patients with ACS and is associated with impaired physical function. Also, the coexistence of MAFLD and lower physical function predict the incidence of clinical events in patients with ACS.

show abstract

Metabolomics and mitochondrial dysfunction in cardiometabolic disease

Shastry,

Dunham-Snary

2023

Life Sciences

View full text Add to dashboard Cite

Multiorgan, Multimodality Imaging in Cardiometabolic Disease

Cited by 8 publications

References 72 publications

A mechanistic framework for cardiometabolic and coronary artery diseases

A mechanistic framework for cardiometabolic and coronary artery diseases

The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome

Metabolomics and mitochondrial dysfunction in cardiometabolic disease

Contact Info

Product

Resources

About